Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-01-05
2008-09-02
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S235100, C424S009100, C435S069100, C435S069700, C530S350000, C514S002600, C514S012200
Reexamination Certificate
active
07419676
ABSTRACT:
Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7132259 (2006-11-01), Dolly et al.
patent: 2006/0024331 (2006-02-01), Fernandez-Salas et al.
patent: 2006/0099672 (2006-05-01), Dolly et al.
patent: 2007/0259401 (2007-11-01), Dolly et al.
patent: 0359347 (1990-03-01), None
patent: WO 95/32738 (1995-12-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 99/55359 (1999-11-01), None
patent: WO01-14570 (2001-03-01), None
patent: WO2004-024909 (2004-03-01), None
Tonello et al, “Tetanus and Botulinum Neurotoxins a Novel Group of Zinc-Endopeptidases”, Intracellular Protein Catabolism, Adv. Exp. Med. & Biol. 389, pp. 251-260 (1996).
Coffield et al, The Site and Mechanism of Action of Botulinum Neurotoxin in Therapy with Botulinum Toxin, pp. 3-13 (1994).
Dolly et al, “Probing the process of transmitter release with botulinum and tetanus neurotoxins” Seminars in Neuroscience, 6 (3): pp. 149-158 (1994).
Foran et al, “Botulinum Neurotoxin C1 Cleaves both Syntaxin and SNAP-25 in Intact and Permeabilized Chromaffin Cells: Correlation with Its Blockade of Catecholamine Release”, Biochem. 35: pp. 2630-2636 (1996).
Borodic et al, “Pharmacology and Histology of the Therapeutic Application of Botulinum Toxin Application of Botulinum Toxins”, pp. 119-157 (1994).
Li et al, “A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen After Reconstitution with Native Heavy Chain”, Biochemistry 33, No. 22: pp. 7014-7020 (1994).
Zhou et al, “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstruction with the Heavy Chain”, Biochemistry 34: pp. 15175-15181 (1995).
Lacy et al, “Crystal structure of botulinum neurotoxin type A and implications for toxicity” Nature Struct. Biol. Oct. 5 (10): pp. 898-902 (1998).
Kurazono et al, “Minimal Essential Domains Specifying Toxicity of the Light Cahins of Tetanus Toxin and Botulinum Neurotoxin Type A”, J. Biol. Chem.: pp. 14271-14729 (1992).
Smith et al, “Mutagenesis at a Specific Position in a DNA Sequence”,J. Biol. Chem. 253: No. 18, Sep. 25 issue, pp. 6651-6560 (1978).
Li et al, “Expression and Characterisation of the Heavy Chain of Tetanus Toxin: Reconstitution of Fully-Recombinant Dichain Protein in Active Form”, J. Biochem. 125: pp. 1200-1208 (1999).
U.S. Appl. No. 60/150,710, filed Aug. 25, 1999, Dolly et al.
U.S. Appl. No. 11/610,440, filed Dec. 13, 2006, Dolly et al.
U.S. Appl. No. 11/781,359, filed Jul. 23, 2007, Dolly et al.
U.S. Appl. No. 11/782,112, filed Jul. 24, 2007, Dolly et al.
U.S. Appl. No. 11/832,108, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/845,167, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/829,475, filed Jul. 27, 2007, Steward et al.
U.S. Appl. No. 11/832,173, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/833,720, filed Aug. 3, 2007, Steward et al.
U.S. Appl. No. 11/834,068, filed Aug. 6, 2007, Steward et al.
U.S. Appl. No. 11/844,780, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,850, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,885, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,929, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,919, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,899, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,517, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,546, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/845,252, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,284, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,320, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,345, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,466, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/833,142, filed Aug. 2, 2007, Steward et al.
Chan Kuo Chion
Dolly J. Oliver
Li Yan
Allergan Inc.
German Joel B.
Kam Chih-Min
Stathakis Dean G.
Voet Martin A.
LandOfFree
Activatable recombinant neurotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activatable recombinant neurotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activatable recombinant neurotoxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3991964